Caris & Co. Downgrades Salix Pharmaceuticals (SLXP) to Above Average
Tweet
Share
E-mailGet Alerts SLXP Hot Sheet
Price: $172.81 --0%
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Caris & Co. downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Above Average. PT raised slightly from $40 to $44.
For more ratings news on Salix Pharmaceuticals click here and for the rating history of Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $40.00 yesterday.
For more ratings news on Salix Pharmaceuticals click here and for the rating history of Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $40.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Canaccord Downgrades Northern Star Resources (NST:AU) (NESRF) to Hold
- Goldman Sachs Downgrades Hysan Development Company Limited (14:HK) (HYSNY) to Sell
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
